DV
Dividend Vision

TLSI — TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc. (TLSI)

Total return is -67.1% over the past 28.6 years, 1274.1 points behind SPY at 1207.0%. Its deepest 1-year drawdown was 66.4%.

TriSalus Life Sciences is a biopharmaceutical company developing drug delivery technology and immuno-oncology therapeutics focused on treating liver and pancreatic cancers. The company's pipeline includes its Pressure-Enabled Drug Delivery platform with the TriNav infusion system for liver cancer procedures, a pancreatic cancer device in Phase 1 trials, and nelitolimod, an immunotherapeutic in early-stage development for multiple cancer types. The company does not currently distribute dividends and appeals to investors seeking exposure to clinical-stage oncology therapeutics rather than current income.

TLSI key facts

Asset type
Stock
Asset class
Equity
Inception date
12/31/1997
Last close
$5.27
Market cap
$266,547,776
Average volume
113800.0
Beta
0.427
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.42